Takeda Pharmaceutical Logo
JP3463000004
853849
4502.T

Takeda Pharmaceutical

Cargando cotizaciones...

Previsión

Comprar
  4
Mantener
  1
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Takeda gets FDA priority review for zasocitinib in plaque psoriasis

    The FDA accepted Takeda's new drug application for zasocitinib under priority review with a target action date in Q1 2027 for adults with moderate-to-severe plaque psoriasis. Phase 3 trials showed strong efficacy (around 70% achieving clear or almost clear skin at week 16 versus ~11% for placebo) and statistical superiority to deucravacitinib on complete skin clearance. Approval, label restrictions, tolerability signals and payer access will determine commercial uptake and real-world revenue potential. » Más en finance.yahoo.com


  • Takeda refocuses on upcoming launches after pipeline investments

    Takeda outlines a two-stage strategy emphasizing heavy pipeline investment and imminent launches (Horizon One), followed by a growth phase (Horizon Two). ORZEYFUL, the orexin agonist for narcolepsy type 1, received FDA approval and is awaiting DEA scheduling ahead of a planned US launch later this year. The selective TYK2 inhibitor zasocitinib has a PDUFA date of 13 March 2027 and is cited with peak sales potential of $3–6 billion for psoriasis/psoriatic arthritis; additional data on inflammatory bowel disease are expected by the end of fiscal 2024. R&D chief Andy Plump is retiring, Julie Kim is expected to shape future strategy; a more detailed update is scheduled for the capital markets day on 11 December in Tokyo. » Más en de.investing.com


  • Takeda: FDA accepts application for psoriasis drug Zasocitinib for priority review

    The FDA has accepted Takeda’s New Drug Application for Zasocitinib (TAK-279) to treat moderate-to-severe plaque psoriasis for priority review; the PDUFA target date is Q1 2027. The EMA has also accepted the marketing application. The submission is supported by two phase III trials in which around 70% of patients achieved nearly clear skin after 16 weeks; key endpoints were met and no new safety signals emerged. Takeda does not expect the submission to have a material impact on consolidated financial guidance for the fiscal year ending 31 March 2027. » Más en de.investing.com


  • Takeda receives FDA approval for blood cancer drug Mimrylo

    The FDA has approved Mimrylo (active ingredient rusfertid) from Takeda for the treatment of erythrocytosis in adults with polycythaemia vera. The decision is based on the phase‑III VERIFY study with 293 patients, in which 76.9% of treated patients showed a clinical response between weeks 20 and 32 and reduced hematocrit levels, fewer phlebotomies, and relief of fatigue were documented. Mimrylo is administered once weekly subcutaneously; common adverse events were injection‑site reactions (56%) and anemia (16%). Takeda holds the exclusive global development and commercialization rights and does not expect an impact on consolidated guidance for the fiscal year. » Más en de.investing.com


  • Takeda receives FDA approval for narcolepsy drug Orzeyful

    The FDA has approved Orzeyful (Oveporexton) from Takeda for the treatment of narcolepsy type 1 in adults. Orzeyful is an oral orexin receptor-2 agonist; the approval is based on two phase‑III studies (FirstLight, RadiantLight) showing significant improvements in daytime sleepiness, cataplexy and quality of life. Common adverse effects were insomnia, increased urination and increased salivation; the drug is contraindicated with strong CYP3A inhibitors. The DEA is still reviewing the controlled-substance scheduling; once that process is complete, dispensing will be via specialty pharmacies. Takeda does not expect a material impact on consolidated financial guidance for the fiscal year ending 31.03.2027. » Más en de.investing.com

En 2026, Takeda Pharmaceutical ya ha pagado 0,54 € en dividendos. El último pago fue en junio.

Datos financieros de la empresa

En el último trimestre, Takeda Pharmaceutical tuvo unos ingresos de 6651,66 M € y un beneficio neto de 1078,24 M €
(EUR) septiembre de 2026
YoY
Ingresos 6651,66 M 3,82 %
Beneficio bruto 4454,64 M 5,59 %
Beneficio neto 1078,24 M 1686,78 %
EBITDA 1831,92 M 7,39 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
62,58 mil M €
Número de acciones
1596,21 M
Máximo/mínimo de 52 semanas
39,70 € - 25,16 €
Rentabilidad por dividendo
2,77 %
Dividendos TTM
1,10 €
Próximo dividendo
0,58 €
Beta
0,09
Ratio P/E
28,48
Ratio PEG
0,03
Ratio P/B
1,47
Ratio P/S
2,37

Perfil de la empresa

Takeda Pharmaceutical Company Limited se dedica a la investigación, el desarrollo, la fabricación, la comercialización y la concesión de licencias de salida (out-licensing) de productos farmacéuticos en todo el mundo. Ofrece productos farmacéuticos en las áreas de gastroenterología; oncología; neurociencia; y enfermedades raras, como las enfermedades metabólicas raras y la hematología, y el angioedema hereditario, así como terapias derivadas del plasma y vacunas. La compañía comercializa sus productos bajo las marcas Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro y Alunbrig. Takeda Pharmaceutical Company tiene acuerdos de licencia con Denali Therapeutics y Wave Life Sciences Ltd; acuerdos de colaboración con Neurocrine Biosciences, Inc. y Rani Therapeutics LLC; acuerdos de licencia e investigación con The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc. y Arrowhead Pharmaceuticals Inc.; acuerdos de colaboración en investigación con Arrowhead Pharmaceuticals Inc. y Ovid Therapeutics Inc.; y una colaboración con Evox Therapeutics Ltd., así como un acuerdo de licencia con ProThera Biologics Inc. También mantiene alianzas estratégicas con Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; y Anima Biotech. Takeda Pharmaceutical Company Limited fue fundada en 1781 y tiene su sede en Tokio, Japón.

Nombre
Takeda Pharmaceutical
CEO
Julie So-Young Kim
Sede Tokyo, os
Japón
Sitio web
Sector
Salud
Industria
Productos farmacéuticos
Salida a bolsa
04/01/2000
Empleados 47.029

Símbolos bursátiles

Bolsa Símbolo
Japan Exchange Group
4502.T
Pnk
TKPHF
Frankfurt
TKD.F
Düsseldorf
TKD.DU
Hamburg
TKD.HM
London
0RN3.L
München
TKD.MU
Wien
TKD.VI
🍪

Parqet  usa cookies. Más información